Новые медицинские технологии в сердечно-сосудистой хирургии. Лечение атеросклероза и его осложнений методом H.E.L.P.-афереза
Download
2. Аронов, Д. М. Лечение и профилактика атеросклероза / Д. М. Аронов. – М., 2000. – С. 9–16.
3. Бокерия, Л. А. Сердечно-сосудистая хирургия – 2005. Болезни и врожденные аномалии системы кровообращения / Л. А. Бокерия, Р. Г. Гудкова. – М.: НЦССХ им. А. Н. Бакулева РАМН, 2006. – С. 4–29.
4. Бокерия, Л. А. Сердечно-сосудистая хирургия – 2002. Болезни и врожденные аномалии системы кровообращения / Л. А. Бокерия, Р. Г. Гудкова. – М.: НЦССХ им. А. Н. Бакулева РАМН, 2003.
5. Бузиашвили, Ю. И. Прогрессирование атеросклероза после коронарной ангиопластики и стентирования у больных ИБС с множественным поражением артерий / Ю. И. Бузиашвили, Э. У. Асымбекова, Р. В. Кипиани и др. // Бюллетень НЦССХ им. А. Н. Бакулева РАМН. – 2005. – Т. 6, № 2. – С. 50–55.
6. Климов, А. Н. Обмен липидов и липопротеидов и его нарушения / А. Н. Климов, Н. Г. Никульчева. – СПб: Питер Ком, 1999.
7. Коновалов, Г. А. Гиполипидемическая терапия и реоферез при дислипопротеидемиях / Г. А. Коновалов, П. В. Звездкин, Т. Л. Хаютина и др. // Consilium medicum. – 2003. – Т. 5, № 11. – С. 22–31.
8. Новые Европейские рекомендации по профилактике и лечению сердечно-сосудистых заболеваний // Доказательная кардиол. – 2003. – Т. 2, № 34. – С. 6.
9. Оганов, Р. Г. Сердечно-сосудистые заболевания в Российской Федерации во второй половине 20 столетия: тенденции, возможные причины, перспективы / Р. Г. Оганов, Г. Я. Масленникова // Кардиология. – 2000. – № 6. – С. 4–8.
10. Ярустовский, М. Б. Возможности коррекции гиперЛп(а)емии методом селективного липафереза в кардиохирургической практике / М. Б. Ярустовский, М. В. Абрамян, М. Г. Плющ // Бюллетень НЦССХ им. А. Н. Бакулева РАМН. Приложение. – 2008. – Т. 9, № 3. – С. 164.
11. Ярустовский, М. Б. Первый опыт применения селективного липафереза в кардиохирургической практике / М. Б. Ярустовский, Р. Г. Григорьянц, М. В. Абрамян // Бюллетень НЦССХ им. А. Н. Бакулева РАМН. – 2005. – № 11. – C. 275.
12. Adachi, H. Prevention of restenosis after coronary angioplasty with low-density lipoprotein apheresis / H. Adachi, A. Niwa, T. Shinoda // Artif. Organ. – 1995. – Vol. 19. – P. 1243–1247.
13. Archontakis, S. LDL-apheresis: indications and clinical experience in a tertiary cardiac centre / S. Archontakis, A. Pottle, N. Hakim et al. // Int. J. Clin. Pract. – 2007. – Vol. 61, № 11. – P. 1834–1842.
14. Armstrong, V. W. Heparin extracorporeal LDL precipitation (HELP): an effective procedure for lowering Lp(a) levels / V. W. Armstrong, P. Stuff- Werner, T. Eisenhauer et al. // Chem. Phys. Lipids. – 1994. – Vol. 67–68. – P. 315–321.
15. Blankenhorn, D. H. Beneficial effects of combined colestipolniacin therapy on coronary atherosclerosis and coronary venous bypass grafts / D. H. Blankenhorn, S. A. Nessim, R. L. Johnson et al. // JAMA. – 1987. – Vol. 257. – P. 3233–3240.
16. Blankenhorn, D. H. Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS) / D. H. Blankenhorn, S. P. Azen, D. M. Kramsch et al.; MARS Research Group. // Ann. Intern. Med. – 1993. – Vol. 119, № 10. – P. 969–976.
17. Blessing, F. Heparin-mediated extracorporeal lowdensity lipoprotein precipitation: rationale for a specific adjuvant therapy in cardiovascular disease / F. Blessing, Y. Wang, A. K. Walli, D. Seidel // Transfus. Apher. Sci. – 2004. – Vol. 30, №3 – P. 255–266.
18. Blessing, F. J. Heparin-mediated extracorporeal LDL precipitation treating a peripheral arterial disease patient suffering from repeated postoperative bypass occlusion / F. J. Blessing, B. Jaeger, Y. Wang et al. // Thromb. Res. – 2005. – Vol. 115. – P. 39–43.__
19. Blessing, F. J. Prevention of early graft occlusion after coronary bypass grafting by post-operative reduction of plasma fibrinogen by H.E.L.P. apheresis. First evaluation of 12 patients treated during our study (44 bypasses) / F. J. Blessing, B. R. Jaeger, M. Oberhoffer et al. // Z. Kardiol. – 2003. – Vol. 92, №3. – P. 42–47.
20. Cantin, B. Is lipoprotein(a) an independent risk factor for ischemic hart disease in men? The Quebec Cardiovascular Study / B. Cantin, F. Gagnon, S. Moorjani et al. // J. Am. Coll. Cardiol. – 1998. – Vol. 31. – P. 519–525.
21. Charlson, M. E. Clinical practice. Care after coronary-artery bypass surgery / M. E. Charlson, O. W. Isom // N. Engl. J. Med. – 2003. – Vol. 348. – P. 1456–1463.
22. Colombo, A. Coronary stenting in 1000 consecutive patients. Long-term clinical and angiographic results / A. Colombo, C. Di Mario, B. Reimers et al. // G. Ital. Cardiol. – 1997. – Vol. 27. – P. 19–31.
23. Demant, T. The metabolism of lipoprotein(a) and other apolipoprotein B-containing lipoproteins: a kinetic study in humans / T. Demant, K. Seeberg, A. Bedynek, D. Seidel // Atherosclerosis. – 2001. – Vol. 157. – P. 325–339.
24. Eisenhauer, T. Selective removal of low density lipoproteins (LDL) by precipitation at low pH; first clinical application of the HELP system / T. Eisenhauer, V. W. Amstrong, H. Wieland et al. // Klin. Woch. – 1987. – Vol. 65. – P. 161–168.
25. Hearn, J. A. Usefulness of serum Lp(a) as a predictor of restenosis after percutaneous transluminal coronary angioplasty / J. A. Hearn, B. C. Donohue, H. Baalbak // Am. J. Cardiol. – 1992. – Vol. 69. – P. 736–739.
26. Hjermann, I. Effect of diet and smoking intervention on the incidence of coronary heart disease. Report from the OSLO study group of a randomized trial in healthy men / I. Hjermann, I. Holme, B. K. Velve, P. Leren // Lancet. – 1981. – Vol. 2. – P. 1303–1310.
27. Hoefler, G. Lipoprotein Lp(a):a risk factor for myocardial infarction / G. Hoefler, F. Harnoncourt, E. Paschke et al. // Atherosclerorsis. – 1988. – Vol. 8. – P. 398–401.
28. Hoff, H. F. Serum Lp(a) level as a predictor of vei graft stenosis after coronary artery bypass surgery in patients / H. F Hoff, G. J. Beck, C. J. Skibinski et al. // Circulation. – 1988. – Vol. 7. – P. 1238–1244.
29. Illigworth, D. Treatment of hyperlipidemia / D. Illigworth // Brit. Med. Bull. – 1990. – Vol. 46, № 4. – P. 1025–1058.
30. Jaeger, B. R. Case reports on emergency treatment of cardiovascular syndromes through heparinmediated low-density lipoprotein/fibrinogen precipitation: a new approach to augment cerebral and myocardial salvage / B. R. Jaeger, E. Kreuzer, A. Knez et al. // Ther. Apher. – 2002. – Vol. 6. – P. 394–398.
31. Jaeger, B. R. Consistent lowering of clotting factors for the treatment of acute cardiovascular syndromes and hypercoagulability: a different pathophysiological approach / B. R. Jaeger, P. Goehring, J. Schirmer et al. // Ther. Apher. – 2001. – Vol. 5. – P. 252–259.
32. Jaeger, B. R. Fibrinogen and atherothrombosis: vulnerable plaque or vulnerable patient? / B. R. Jaeger, C. A. Labarrere // Herz. – 2003. – Vol. 28, № 6. – P. 530–538.
33. Jaeger, B. R. Heparin-mediated extracorporeal LDL/fibrinogen precipitation—H.E.L.P.—in coronary and cerebral ischemia / B. R. Jaeger, P. Marx, T. Pfefferkorn et al. // Acta Neurochir. – 1999. – Vol. 73. – P. 81–84 (Suppl.).
34. Jaeger, B. R. Hyperlipoproteinemia and LDL apheresis. Clinical experiences with the H.E.L.P. system / B. R. Jaeger, D. Seidel // Herz. – 2001. – Vol. 26. – P. 531–544.
35. Kroon, A. A. LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis / A. A. Kroon, W. R. Aengevaeren, T. van der Werf et al. // Circulation. – 1996. – Vol. 15, № 93 (10). – P. 1826–1835.
36. Lane, D. Selective removal of plasma low density lipoprotein with the HELP system: biweekly versus weekly therapy / D. Lane, W. J. McConathy, L. O. Laughlin et al. // Atherosclerosis. – 1995. – Vol. 114. – P. 203–211.
37. McMichael, J. Diet and exercise in coronary heart disease / J. McMichael // Lancet. – 1974. – Vol. 29. – P. 1340–1341.
38. Mellwig, K. P. Heparin-induced extracorporeal lowdensity lipoprotein precipitation / K. P. Mellwig // Ther. Apher. Dial. – 2003. – Vol. 7, № 3. – P. 365–369.
39. Mellwig, K. P. Improved coronary vasodilatatory capacity by H.E.L.P. apheresis: comparing initial and chronic treatment / K. P. Mellwig, F. van Buuren, H. K. Schmidt et al. // Ther. Apher. Dial. – 2006. – Vol. 10, № 6. – P. 510–517.
40. Mellwig, K. P. Myocardial perfusion under H.E.L.P.- apheresis. Objectification by PET / K. P. Mellwig, D. Baller, H. K. Schmidt et al. // Z. Kardiol. – 2003. – Vol. 92. – P. 30–37 (Suppl. 3).
41. Moriarty, P. M. C-reactive protein and other markers of inflammation among patients undergoing HELP LDL apheresis / P. M. Moriarty, C. A. Gibson, J. Shih, M. S. Matias // Atherosclerosis. – 2001. – Vol. 158. – P. 495–498.
42. Ost, C. R. Regression of peripheral atherosclerosis during therapy with high doses of nicotinic acid / C. R. Ost, S. Stenson // Scand. J. Clin. Lab. Invest. – 1967. – Vol. 99. – P. 241–245 (Suppl.).
43. Parhofer, K. G. Efficacy of different low-density lipoprotein apheresis methods / K. G. Parhofer, H. C. Geiss, P. Schwandt // Ther. Apher. – 2000. – Vol. 4. – P. 382–385.
44. Park, J. W. Effect of HELP-LDL-apheresis on outcomes in patients with advanced coronary atherosclerosis and severe hypercholesterolemia / J. W. Park, M. Merz, P. Braun // Atherosclerosis. – 1998. – Vol. 139. – P. 401–409.
45. Park, J. W. Regression of transplant coronary artery disease during chronic low-density lipoprotein apheresis / J. W. Park, M. Merz, P. Braun // J. Heart Lung. Transpl. – 1997. – Vol. 16, № 3. – P. 290–297.
46. Pokrovsky, S. N. Association of lipoprotein(a) excess with early vein graft occlusion in middleaged men undergoing coronary artery bypass surgery / S. N. Pokrovsky, M. V. Ezhov, L. N. Il’ina et al. // J. Thorac. Cardiovasc. Surg. – 2003. – Vol. 126, № 4. – P. 1071–1075.
47. Pulawski, E. H.E.L.P. apheresis and oxidative stress / E. Pulawski, K. P. Mellwig, D. Horstkotte // Z. Kardiol. – 2003. – Vol. 92. – P. III 38–41 (Suppl. 3).
48. Pulawski, E. Influence of single low-density lipoprotein apheresis on the adhesion molecules soluble vascular cellular adhesion molecule-1, soluble intercellular adhesion molecule-1, and P-selectin / E. Pulawski, K. P. Mellwig, T. Brinkmann et al. // Ther. Apher. – 2002. – Vol. 6. – P. 229–233.
49. Ramunni, A. Effectiveness of long-term heparininduced extracorporeal LDL precipitation (HELP) in improving coronary calcifications / A. Ramunni, L. F. Morrone, G. Baldassarre et al. // Int. J. Artif. Organs. – 2003. – Vol. 26, № 3. – P. 252–255.
50. Richter, W. O. Three low density lipoprotein apheresis techniques in treatment of patients with familial hypercholesterolemia: a long-term evaluation / W. O. Richter, M. G. Donner, P. Schwandt // Ther. Apher. – 1999. – Vol. 3. – P. 203–208.
51. Schettler, V. Acute effect of H.E.L.P. treatment on radical scavenging enzyme activities, total glutathione concentrations in granulocytes, and selenium in plasma / V Schettler., H. Methe, P. Schuff- Werner et al. // Eur. J. Clin. Invest. – 2000. – Vol. 30, № 1. – P. 26–32.
52. Schmaldienst, S. Prospective randomized cross-over comparison oh three LDL-apheresis system in statin pretreated patients with familial hypercholesterolemia / S. Schmaldienst, S. Banyai, T. M. Stulnig et al. // Atherosclerosis. – 2000. – Vol. 151. – P. 493–499.
53. Schuff-Werner, P. Clinical long-term results of H.E.L.P.-apheresis / P. Schuff-Werner // Z. Kardiol. – 2003. – Vol. 92. – P. 28–29 (Suppl. 3).
54. Schuff-Werner, P. Fibrinogen lowering by apheresis: efficiency of different methods and possible clinical implications / P. Schuff-Werner, E. Schutz, H. Beyer // Jpn. J. Apheresis. – 1997. – Vol. 16, № 1. – P. 317–318.
55. Seidel, D. LDL-apheresis in the treatment of coronary heart disease. Rationale for a specific adjuvant therapy / D. Seidel // Z. Kardiol. – 2003. – Vol. 92. – P. 6–27.
56. Seiler, C. Influence of serum cholesterol and other coronary risk factors on vasomotion of angiographically normal coronary arteries / C. Seiler, O. M. Hess, M. Buechi et al. // Circulation. – 1993. – Vol. 88. – P. 2139–2148.
57. The HELP-Study Group. The HELP-LDLapheresis multicentre study: an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease. I. Evaluation of safety and cholesterol-lowering effects during the first 12 months / D. Seidel, V. W. Armstrong, P. Schuff-Werner // Eur. J. Clin. Invest. – 1991. – Vol. 21. – P. 375–383.
58. The HELP-Study Group. The HELP-LDLapheresis multicentre study, an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease. II. Final evaluation of the effect of regular treatment on LDL-cholesterol plasma concentrations and the course of coronary heart disease / P. Schuff-Werner, H. Gohlke, U. Bartmann et al. // Eur. J. Clin. Invest. – 1994. – Vol. 24. – P. 724–732.
59. Thiery, J. Safety and effectiveness of long-term LDL-apheresis in patients at high risk / J. Thiery, D. Seidel // Curr. Opin. Lipidol. – 1998. – Vol. 9. – P. 521–526.
60. Thompsen, J. A systematic review of LDL apheresis in the treatment of cardiovascular disease / J. Thompsen, P. D. Thompson // Atherosclerosis. – 2006. – Vol. 189, № 1. – P. 31–38.
61. Thompson, G. R. Assessment of long-term plasma exchange for familial hypercholesterolaemia / G. R. Thompson, N. B. Myant, D. Kilpatrick et al. // Br. Heart J. – 1980. – Vol. 43. – P. 680–688.
62. Thompson, G. R. Familial Hypercholesterolaemia Regression Study: a randomised trial of low-density- lipoprotein apheresis. (FHRS) / G. R. Thompson, V. M. Maher, S. Matthews et al. // Lancet. – 1995. – Vol. 345, № 8953. – P. 811–816.
63. Thompson, G. R. Handbook of hyperlipidaemia / G. R. Thompson. – London: MSD Co., 1989. – P. 236–238.
64. Thompson, G. R. LDL apheresis / G. R. Thompson // Atherosclerosis. – 2003. – Vol. 167. – P. 1–13.
65. Thompson, G. R. Percentage change rather than plasma level of LDLcholesterol determines therapeutic response in coronary heart disease / G. R. Thompson, J. Holyer, D. D. Waters // Curr. Opinion. Lipidol. – 1995. – Vol. 6. – P. 386–388.
66. Thompson, G. R. Plasma exchange in the management of homozygous familial hypercholesterolaemia / G. R. Thompson, R. Lowenthal, R. Myant // Lancet. – 1975. – Vol. 1. – P. 1208–1211.
67. Wang, Y. Effects of heparin-mediated extracorporeal low-density lipoprotein precipitation beyond lowering proatherogenic lipoproteins—reduction of circulating proinflammatory and procoagulatory markers / Y. Wang, F. Blessing, A. K. Walli et al. // Atherosclerosis. – 2004. – Vol. 175. – P. 145–150.
68. Williams, D. O. Percutaneous coronary intervention in the current era compared with 1985–1986: The National Heart, Lung and Blood Institute Registry / D. O. Williams, R. Holubkov, W. W. Yeh et al. // Circulation. – 2000. – Vol. 102. – P. 2945–2951.
69. Yokoyama, S. Selective removal of low density lipoprotein by plasmapheresis in familial hypercholesterolaemia / S. Yokoyama, R. Hayashi, M. Satani, A. Yamamoto // Arteriosclerosis. – 1985. – Vol. 5. – P. 613–622.
References
1. Абрамян, М. В. Возможности липафереза в комплексном лечении атеросклероза / М. В. Абрамян // Креат. кардиол. – 2007. – № 1–2. – С. 208–220.2. Аронов, Д. М. Лечение и профилактика атеросклероза / Д. М. Аронов. – М., 2000. – С. 9–16.
3. Бокерия, Л. А. Сердечно-сосудистая хирургия – 2005. Болезни и врожденные аномалии системы кровообращения / Л. А. Бокерия, Р. Г. Гудкова. – М.: НЦССХ им. А. Н. Бакулева РАМН, 2006. – С. 4–29.
4. Бокерия, Л. А. Сердечно-сосудистая хирургия – 2002. Болезни и врожденные аномалии системы кровообращения / Л. А. Бокерия, Р. Г. Гудкова. – М.: НЦССХ им. А. Н. Бакулева РАМН, 2003.
5. Бузиашвили, Ю. И. Прогрессирование атеросклероза после коронарной ангиопластики и стентирования у больных ИБС с множественным поражением артерий / Ю. И. Бузиашвили, Э. У. Асымбекова, Р. В. Кипиани и др. // Бюллетень НЦССХ им. А. Н. Бакулева РАМН. – 2005. – Т. 6, № 2. – С. 50–55.
6. Климов, А. Н. Обмен липидов и липопротеидов и его нарушения / А. Н. Климов, Н. Г. Никульчева. – СПб: Питер Ком, 1999.
7. Коновалов, Г. А. Гиполипидемическая терапия и реоферез при дислипопротеидемиях / Г. А. Коновалов, П. В. Звездкин, Т. Л. Хаютина и др. // Consilium medicum. – 2003. – Т. 5, № 11. – С. 22–31.
8. Новые Европейские рекомендации по профилактике и лечению сердечно-сосудистых заболеваний // Доказательная кардиол. – 2003. – Т. 2, № 34. – С. 6.
9. Оганов, Р. Г. Сердечно-сосудистые заболевания в Российской Федерации во второй половине 20 столетия: тенденции, возможные причины, перспективы / Р. Г. Оганов, Г. Я. Масленникова // Кардиология. – 2000. – № 6. – С. 4–8.
10. Ярустовский, М. Б. Возможности коррекции гиперЛп(а)емии методом селективного липафереза в кардиохирургической практике / М. Б. Ярустовский, М. В. Абрамян, М. Г. Плющ // Бюллетень НЦССХ им. А. Н. Бакулева РАМН. Приложение. – 2008. – Т. 9, № 3. – С. 164.
11. Ярустовский, М. Б. Первый опыт применения селективного липафереза в кардиохирургической практике / М. Б. Ярустовский, Р. Г. Григорьянц, М. В. Абрамян // Бюллетень НЦССХ им. А. Н. Бакулева РАМН. – 2005. – № 11. – C. 275.
12. Adachi, H. Prevention of restenosis after coronary angioplasty with low-density lipoprotein apheresis / H. Adachi, A. Niwa, T. Shinoda // Artif. Organ. – 1995. – Vol. 19. – P. 1243–1247.
13. Archontakis, S. LDL-apheresis: indications and clinical experience in a tertiary cardiac centre / S. Archontakis, A. Pottle, N. Hakim et al. // Int. J. Clin. Pract. – 2007. – Vol. 61, № 11. – P. 1834–1842.
14. Armstrong, V. W. Heparin extracorporeal LDL precipitation (HELP): an effective procedure for lowering Lp(a) levels / V. W. Armstrong, P. Stuff- Werner, T. Eisenhauer et al. // Chem. Phys. Lipids. – 1994. – Vol. 67–68. – P. 315–321.
15. Blankenhorn, D. H. Beneficial effects of combined colestipolniacin therapy on coronary atherosclerosis and coronary venous bypass grafts / D. H. Blankenhorn, S. A. Nessim, R. L. Johnson et al. // JAMA. – 1987. – Vol. 257. – P. 3233–3240.
16. Blankenhorn, D. H. Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS) / D. H. Blankenhorn, S. P. Azen, D. M. Kramsch et al.; MARS Research Group. // Ann. Intern. Med. – 1993. – Vol. 119, № 10. – P. 969–976.
17. Blessing, F. Heparin-mediated extracorporeal lowdensity lipoprotein precipitation: rationale for a specific adjuvant therapy in cardiovascular disease / F. Blessing, Y. Wang, A. K. Walli, D. Seidel // Transfus. Apher. Sci. – 2004. – Vol. 30, №3 – P. 255–266.
18. Blessing, F. J. Heparin-mediated extracorporeal LDL precipitation treating a peripheral arterial disease patient suffering from repeated postoperative bypass occlusion / F. J. Blessing, B. Jaeger, Y. Wang et al. // Thromb. Res. – 2005. – Vol. 115. – P. 39–43.__
19. Blessing, F. J. Prevention of early graft occlusion after coronary bypass grafting by post-operative reduction of plasma fibrinogen by H.E.L.P. apheresis. First evaluation of 12 patients treated during our study (44 bypasses) / F. J. Blessing, B. R. Jaeger, M. Oberhoffer et al. // Z. Kardiol. – 2003. – Vol. 92, №3. – P. 42–47.
20. Cantin, B. Is lipoprotein(a) an independent risk factor for ischemic hart disease in men? The Quebec Cardiovascular Study / B. Cantin, F. Gagnon, S. Moorjani et al. // J. Am. Coll. Cardiol. – 1998. – Vol. 31. – P. 519–525.
21. Charlson, M. E. Clinical practice. Care after coronary-artery bypass surgery / M. E. Charlson, O. W. Isom // N. Engl. J. Med. – 2003. – Vol. 348. – P. 1456–1463.
22. Colombo, A. Coronary stenting in 1000 consecutive patients. Long-term clinical and angiographic results / A. Colombo, C. Di Mario, B. Reimers et al. // G. Ital. Cardiol. – 1997. – Vol. 27. – P. 19–31.
23. Demant, T. The metabolism of lipoprotein(a) and other apolipoprotein B-containing lipoproteins: a kinetic study in humans / T. Demant, K. Seeberg, A. Bedynek, D. Seidel // Atherosclerosis. – 2001. – Vol. 157. – P. 325–339.
24. Eisenhauer, T. Selective removal of low density lipoproteins (LDL) by precipitation at low pH; first clinical application of the HELP system / T. Eisenhauer, V. W. Amstrong, H. Wieland et al. // Klin. Woch. – 1987. – Vol. 65. – P. 161–168.
25. Hearn, J. A. Usefulness of serum Lp(a) as a predictor of restenosis after percutaneous transluminal coronary angioplasty / J. A. Hearn, B. C. Donohue, H. Baalbak // Am. J. Cardiol. – 1992. – Vol. 69. – P. 736–739.
26. Hjermann, I. Effect of diet and smoking intervention on the incidence of coronary heart disease. Report from the OSLO study group of a randomized trial in healthy men / I. Hjermann, I. Holme, B. K. Velve, P. Leren // Lancet. – 1981. – Vol. 2. – P. 1303–1310.
27. Hoefler, G. Lipoprotein Lp(a):a risk factor for myocardial infarction / G. Hoefler, F. Harnoncourt, E. Paschke et al. // Atherosclerorsis. – 1988. – Vol. 8. – P. 398–401.
28. Hoff, H. F. Serum Lp(a) level as a predictor of vei graft stenosis after coronary artery bypass surgery in patients / H. F Hoff, G. J. Beck, C. J. Skibinski et al. // Circulation. – 1988. – Vol. 7. – P. 1238–1244.
29. Illigworth, D. Treatment of hyperlipidemia / D. Illigworth // Brit. Med. Bull. – 1990. – Vol. 46, № 4. – P. 1025–1058.
30. Jaeger, B. R. Case reports on emergency treatment of cardiovascular syndromes through heparinmediated low-density lipoprotein/fibrinogen precipitation: a new approach to augment cerebral and myocardial salvage / B. R. Jaeger, E. Kreuzer, A. Knez et al. // Ther. Apher. – 2002. – Vol. 6. – P. 394–398.
31. Jaeger, B. R. Consistent lowering of clotting factors for the treatment of acute cardiovascular syndromes and hypercoagulability: a different pathophysiological approach / B. R. Jaeger, P. Goehring, J. Schirmer et al. // Ther. Apher. – 2001. – Vol. 5. – P. 252–259.
32. Jaeger, B. R. Fibrinogen and atherothrombosis: vulnerable plaque or vulnerable patient? / B. R. Jaeger, C. A. Labarrere // Herz. – 2003. – Vol. 28, № 6. – P. 530–538.
33. Jaeger, B. R. Heparin-mediated extracorporeal LDL/fibrinogen precipitation—H.E.L.P.—in coronary and cerebral ischemia / B. R. Jaeger, P. Marx, T. Pfefferkorn et al. // Acta Neurochir. – 1999. – Vol. 73. – P. 81–84 (Suppl.).
34. Jaeger, B. R. Hyperlipoproteinemia and LDL apheresis. Clinical experiences with the H.E.L.P. system / B. R. Jaeger, D. Seidel // Herz. – 2001. – Vol. 26. – P. 531–544.
35. Kroon, A. A. LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis / A. A. Kroon, W. R. Aengevaeren, T. van der Werf et al. // Circulation. – 1996. – Vol. 15, № 93 (10). – P. 1826–1835.
36. Lane, D. Selective removal of plasma low density lipoprotein with the HELP system: biweekly versus weekly therapy / D. Lane, W. J. McConathy, L. O. Laughlin et al. // Atherosclerosis. – 1995. – Vol. 114. – P. 203–211.
37. McMichael, J. Diet and exercise in coronary heart disease / J. McMichael // Lancet. – 1974. – Vol. 29. – P. 1340–1341.
38. Mellwig, K. P. Heparin-induced extracorporeal lowdensity lipoprotein precipitation / K. P. Mellwig // Ther. Apher. Dial. – 2003. – Vol. 7, № 3. – P. 365–369.
39. Mellwig, K. P. Improved coronary vasodilatatory capacity by H.E.L.P. apheresis: comparing initial and chronic treatment / K. P. Mellwig, F. van Buuren, H. K. Schmidt et al. // Ther. Apher. Dial. – 2006. – Vol. 10, № 6. – P. 510–517.
40. Mellwig, K. P. Myocardial perfusion under H.E.L.P.- apheresis. Objectification by PET / K. P. Mellwig, D. Baller, H. K. Schmidt et al. // Z. Kardiol. – 2003. – Vol. 92. – P. 30–37 (Suppl. 3).
41. Moriarty, P. M. C-reactive protein and other markers of inflammation among patients undergoing HELP LDL apheresis / P. M. Moriarty, C. A. Gibson, J. Shih, M. S. Matias // Atherosclerosis. – 2001. – Vol. 158. – P. 495–498.
42. Ost, C. R. Regression of peripheral atherosclerosis during therapy with high doses of nicotinic acid / C. R. Ost, S. Stenson // Scand. J. Clin. Lab. Invest. – 1967. – Vol. 99. – P. 241–245 (Suppl.).
43. Parhofer, K. G. Efficacy of different low-density lipoprotein apheresis methods / K. G. Parhofer, H. C. Geiss, P. Schwandt // Ther. Apher. – 2000. – Vol. 4. – P. 382–385.
44. Park, J. W. Effect of HELP-LDL-apheresis on outcomes in patients with advanced coronary atherosclerosis and severe hypercholesterolemia / J. W. Park, M. Merz, P. Braun // Atherosclerosis. – 1998. – Vol. 139. – P. 401–409.
45. Park, J. W. Regression of transplant coronary artery disease during chronic low-density lipoprotein apheresis / J. W. Park, M. Merz, P. Braun // J. Heart Lung. Transpl. – 1997. – Vol. 16, № 3. – P. 290–297.
46. Pokrovsky, S. N. Association of lipoprotein(a) excess with early vein graft occlusion in middleaged men undergoing coronary artery bypass surgery / S. N. Pokrovsky, M. V. Ezhov, L. N. Il’ina et al. // J. Thorac. Cardiovasc. Surg. – 2003. – Vol. 126, № 4. – P. 1071–1075.
47. Pulawski, E. H.E.L.P. apheresis and oxidative stress / E. Pulawski, K. P. Mellwig, D. Horstkotte // Z. Kardiol. – 2003. – Vol. 92. – P. III 38–41 (Suppl. 3).
48. Pulawski, E. Influence of single low-density lipoprotein apheresis on the adhesion molecules soluble vascular cellular adhesion molecule-1, soluble intercellular adhesion molecule-1, and P-selectin / E. Pulawski, K. P. Mellwig, T. Brinkmann et al. // Ther. Apher. – 2002. – Vol. 6. – P. 229–233.
49. Ramunni, A. Effectiveness of long-term heparininduced extracorporeal LDL precipitation (HELP) in improving coronary calcifications / A. Ramunni, L. F. Morrone, G. Baldassarre et al. // Int. J. Artif. Organs. – 2003. – Vol. 26, № 3. – P. 252–255.
50. Richter, W. O. Three low density lipoprotein apheresis techniques in treatment of patients with familial hypercholesterolemia: a long-term evaluation / W. O. Richter, M. G. Donner, P. Schwandt // Ther. Apher. – 1999. – Vol. 3. – P. 203–208.
51. Schettler, V. Acute effect of H.E.L.P. treatment on radical scavenging enzyme activities, total glutathione concentrations in granulocytes, and selenium in plasma / V Schettler., H. Methe, P. Schuff- Werner et al. // Eur. J. Clin. Invest. – 2000. – Vol. 30, № 1. – P. 26–32.
52. Schmaldienst, S. Prospective randomized cross-over comparison oh three LDL-apheresis system in statin pretreated patients with familial hypercholesterolemia / S. Schmaldienst, S. Banyai, T. M. Stulnig et al. // Atherosclerosis. – 2000. – Vol. 151. – P. 493–499.
53. Schuff-Werner, P. Clinical long-term results of H.E.L.P.-apheresis / P. Schuff-Werner // Z. Kardiol. – 2003. – Vol. 92. – P. 28–29 (Suppl. 3).
54. Schuff-Werner, P. Fibrinogen lowering by apheresis: efficiency of different methods and possible clinical implications / P. Schuff-Werner, E. Schutz, H. Beyer // Jpn. J. Apheresis. – 1997. – Vol. 16, № 1. – P. 317–318.
55. Seidel, D. LDL-apheresis in the treatment of coronary heart disease. Rationale for a specific adjuvant therapy / D. Seidel // Z. Kardiol. – 2003. – Vol. 92. – P. 6–27.
56. Seiler, C. Influence of serum cholesterol and other coronary risk factors on vasomotion of angiographically normal coronary arteries / C. Seiler, O. M. Hess, M. Buechi et al. // Circulation. – 1993. – Vol. 88. – P. 2139–2148.
57. The HELP-Study Group. The HELP-LDLapheresis multicentre study: an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease. I. Evaluation of safety and cholesterol-lowering effects during the first 12 months / D. Seidel, V. W. Armstrong, P. Schuff-Werner // Eur. J. Clin. Invest. – 1991. – Vol. 21. – P. 375–383.
58. The HELP-Study Group. The HELP-LDLapheresis multicentre study, an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease. II. Final evaluation of the effect of regular treatment on LDL-cholesterol plasma concentrations and the course of coronary heart disease / P. Schuff-Werner, H. Gohlke, U. Bartmann et al. // Eur. J. Clin. Invest. – 1994. – Vol. 24. – P. 724–732.
59. Thiery, J. Safety and effectiveness of long-term LDL-apheresis in patients at high risk / J. Thiery, D. Seidel // Curr. Opin. Lipidol. – 1998. – Vol. 9. – P. 521–526.
60. Thompsen, J. A systematic review of LDL apheresis in the treatment of cardiovascular disease / J. Thompsen, P. D. Thompson // Atherosclerosis. – 2006. – Vol. 189, № 1. – P. 31–38.
61. Thompson, G. R. Assessment of long-term plasma exchange for familial hypercholesterolaemia / G. R. Thompson, N. B. Myant, D. Kilpatrick et al. // Br. Heart J. – 1980. – Vol. 43. – P. 680–688.
62. Thompson, G. R. Familial Hypercholesterolaemia Regression Study: a randomised trial of low-density- lipoprotein apheresis. (FHRS) / G. R. Thompson, V. M. Maher, S. Matthews et al. // Lancet. – 1995. – Vol. 345, № 8953. – P. 811–816.
63. Thompson, G. R. Handbook of hyperlipidaemia / G. R. Thompson. – London: MSD Co., 1989. – P. 236–238.
64. Thompson, G. R. LDL apheresis / G. R. Thompson // Atherosclerosis. – 2003. – Vol. 167. – P. 1–13.
65. Thompson, G. R. Percentage change rather than plasma level of LDLcholesterol determines therapeutic response in coronary heart disease / G. R. Thompson, J. Holyer, D. D. Waters // Curr. Opinion. Lipidol. – 1995. – Vol. 6. – P. 386–388.
66. Thompson, G. R. Plasma exchange in the management of homozygous familial hypercholesterolaemia / G. R. Thompson, R. Lowenthal, R. Myant // Lancet. – 1975. – Vol. 1. – P. 1208–1211.
67. Wang, Y. Effects of heparin-mediated extracorporeal low-density lipoprotein precipitation beyond lowering proatherogenic lipoproteins—reduction of circulating proinflammatory and procoagulatory markers / Y. Wang, F. Blessing, A. K. Walli et al. // Atherosclerosis. – 2004. – Vol. 175. – P. 145–150.
68. Williams, D. O. Percutaneous coronary intervention in the current era compared with 1985–1986: The National Heart, Lung and Blood Institute Registry / D. O. Williams, R. Holubkov, W. W. Yeh et al. // Circulation. – 2000. – Vol. 102. – P. 2945–2951.
69. Yokoyama, S. Selective removal of low density lipoprotein by plasmapheresis in familial hypercholesterolaemia / S. Yokoyama, R. Hayashi, M. Satani, A. Yamamoto // Arteriosclerosis. – 1985. – Vol. 5. – P. 613–622.
